Navigation Links
Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market
Date:8/12/2009

LONDON, Aug. 12 /PRNewswire/ -- The challenge to manage adverse events in an optimal and efficient way and, at the same time, adhere to regulatory requirements has dictated the need for cutting edge pharmacovigilance tools and technologies.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.healthcareIT.frost.com), World Pharmacovigilance Markets in Lifesciences, finds that the world pharmacovigilance market was worth $1859.9 million in 2008 and is estimated to reach $2252.2 million in 2015. In this study, Frost & Sullivan's expert analysts thoroughly examine the following technologies: drug safety database systems and signal detection systems.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by e-mail.

"Regulatory bodies such as the Food & Drug Administration (FDA) and European Medicines Agency (EMEA) are intensifying safety regulations, thereby boosting the adoption rates of pharmacovigilance systems by pharmaceutical companies," notes Frost & Sullivan Senior Analyst E.Sujith. "The need to operate in a cost-effective way is inducing pharmaceutical companies to outsource/offshore their pharmacovigilance operations."

For large companies, the volume of adverse events is sizeable. Even a product from a mid-size company can generate a high volume of adverse events. There is significant potential for outsourcing/offhsoring for mid-sized companies as well.

Most top pharmaceutical companies have well-established systems and processes. Consequently, they are not willing to replace these systems as this entails high costs and is also time consuming.

Moreover, the migration of data from one system to another tends to be expensive for most companies. Aligning existing processes to fit in the new system is difficult.

Vendors should educate pharmaceutical companies about technology implications and its importance in their day-to-day operations. This will be necessary to overcoming prevailing skepticism about a new technology and its merits. They should conduct seminars and conferences to trigger interest and make pharmaceutical companies understand that technology that functions optimally can offer substantial return on investments.

"There will be advances in data integration that will support more flexible decision making on drug safety issues," remarks Sujith. "There is significant scope to extend pharmacovigilance systems to boost their integration with a range of other data sources such as medical records and clinical data."

World Pharmacovigilance Markets in Lifesciences is part of the Healthcare & Life Sciences IT Growth Partnership Service program, which also includes research in the following markets: CRM Solutions Markets in Life Sciences, Imaging Solutions in Life Sciences Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

World Pharmacovigilance Markets in Lifesciences

M3A2

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49 (0) 69 7703343
    E: katja.feick@frost.com
   http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Outsourcing of IT Requirements by Healthcare Organisations Promotes All-Round Benefits, Says Frost & Sullivan
2. Frost & Sullivan Awards Agfa Healthcare for Brazilian Market Penetration Leadership in 2009
3. Radiology Informatics: Frost & Sullivan Examines the Next Big Wave in Medicine
4. Prescient Medical Receives Frost & Sullivan Product Innovation of the Year Award
5. Frost & Sullivan Examines the Key Challenges in the European Non-Invasive Ventilation Market
6. Frost & Sullivan Examines the Key Challenges in the European Non-Invasive Ventilation Market
7. Growth in African Medical Imaging Markets: Frost & Sullivan Examines the Potential
8. Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders, Advises Frost & Sullivan
9. Frost & Sullivan Lauds Marigot Ltd. and GTC Nutrition for Their Innovative CalciLife(TM)
10. Frost & Sullivan Identifies Innovative and Cost-Effective Technology as Key Competitive Factor in European Medical Device Market
11. Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... WA (PRWEB) , ... May 05, 2016 , ... ... ranking for overall select performance in the industry’s gold standard KLAS ... The Epic Consulting report assessed organizations that specialize in consulting services for ...
(Date:5/5/2016)... ... May 05, 2016 , ... The U.S. Food and Drug ... manufacturers to submit their products through an arduous federal approval process. The rules, ... entered the market since February 15, 2007. That would essentially ban 99 percent ...
(Date:5/5/2016)... , ... May 05, 2016 , ... TLC Laser Eye ... Diego, California. The laser eye center will now be called “Gordon Schanzlin New Vision ... staff will remain at the full-service facility to ensure that patients continue to receive ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... ultraviolet light A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested ... seaweeds. The pair observed that when photosynthetically active radiation (i.e. the white light ...
(Date:5/5/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... addition to its family of Partner Firms. Headquartered in Mount Pleasant, South Carolina, ... and health care consumerism specialists. , “Partnering with UBA will enable our firm ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... May 5, 2016 Endo International plc (NASDAQ: ... Douglas S. Ingram , former president of Allergan, Inc. ... B. Sisitsky , managing partner of TPG Capital, to its ... "Endo recently embarked on a ... and expand the Board,s capabilities. Doug and Todd are experienced ...
(Date:5/5/2016)... 2016  Diagnostic imaging has been on the ... that these tests cause health care costs to spike. However, ... well as the adoption of new guidelines are ... that help health care providers cut costs, while helping patients ... a renowned authorized reseller of the medical industry,s ...
(Date:5/5/2016)... , May 5, 2016 /PRNewswire/ ... announced the addition of the  "Europe ... - 2016"  report to their offering.  ... ) , ,The latest research ... Highlights - 2016, provides comprehensive insights ...
Breaking Medicine Technology: